

P22618.A02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kouichi SEKIYA et al.

Group Art Unit : 1624

Appln. No : 10/631,795

Examiner : Unknown

Filed : August 1, 2003

For : PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE
ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. 1.56, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98, and in conformance with MPEP 609 and 37 C.F.R. 1.98(d).

Applicants hereby make of record the Information Disclosure Statement filed February 11, 2002, and the Clarification Regarding Cited Information filed June 17, 2003, and the information cited by the Examiner in the Office Action mailed September 13, 2003, January 17, 2003, and May 2, 2003 in Application No. 09/926,477.

The Examiner is respectfully requested to consider the documents cited in the parent application, and to make the documents cited therein of record in the instant application.

Applicants note that copies of documents cited in the above-mentioned disclosure statement have been submitted in parent Application No. 09/926,477. Accordingly, pursuant to 37 C.F.R.

P22618.A02

1.98(d) copies of the documents are not being submitted herewith, and the Examiner is invited to review and consider the documents in the parent application. Of course, should any of the documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.


For the convenience of the Examiner, the above-noted documents cited in the parent applications are listed on the attached Forms PTO-1449. The Examiner is requested to initial the Forms PTO-1449, and to return the initialed copy with the next communication from the U.S. Patent and Trademark Office.

Furthermore, Applicants also once again bring to the Examiner's attention Patent Application No. 09/554,077 filed November 12, 1998 which is the National Stage of PCT/JP98/05092 as well as its continuation Application No. 10/200,576 filed July 23, 2003. Copies of these applications are enclosed for consideration by the Examiner. In accordance with 37 C.F.R. §1.98(a)(2)(iii), copies of the above-mentioned applications are attached hereto. However, the Examiner is also requested to review the file wrapper of these U.S. patent applications at the U.S. Patent and Trademark Office and the references of record, if any, cited therein. In this regard, the applications are not listed on the form PTO-1449 because they are not publications.

P22618.A02

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully submitted,
Kouichi SEKIYA et al.


Bruce H. Bernstein
Reg. No. 29,027

November 3, 2003
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P22618Serial No.
10/631,795INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Kouichi SEKIYA et al.Filing Date
August 1, 2003Group
1624

NOV 03 2003

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 9 4 8 9 1 3	09/07/99	YAMAMOTO et al.			
	5 8 6 1 4 0 4	01/19/99	NIEWÖHMER et al.			
	5 7 7 0 6 1 1	06/23/98	BROWN			
	5 1 2 4 4 5 5	06/23/92	LOMBARDO			
	4 1 9 3 9 2 6	03/18/80	SCHMIECHEN et al.			
	4 0 1 2 4 9 5	03/15/77	SCHMIECHEN et al.			
	3 9 3 6 4 5 4	02/03/76	SCHWENDER			
	3 8 6 2 1 8 9	01/21/75	SCHWENDER			


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	2 1 6 7 3 5 3	07/20/96	CANADA			
8 -	2 3 1 5 4 5	09/10/96	JAPAN			
0 0 /	6 8 2 3 1	11/16/00	W.I.P.O.			
9 9 /	2 4 4 3 2	05/20/99	W.I.P.O.			
1	0 4 3 3 2 4	10/11/00	E.P.O.			
9 6 /	3 6 6 0 6	11/21/96	W.I.P.O.			
9 6 /	2 6 9 4 2	09/06/96	W.I.P.O.			
9 6 /	2 6 2 0 9	08/29/96	W.I.P.O.			
9 5 /	1 8 8 1 5	07/13/95	W.I.P.O.			
9 5 /	1 0 5 2 5	04/20/95	W.I.P.O.			
9 5 /	0 0 5 1 6	01/05/95	W.I.P.O.			
9 4 /	1 4 7 4 2	07/07/94	W.I.P.O.			
9 4 /	1 2 4 6 1	06/09/94	W.I.P.O.			
9 4 /	1 1 0 0 4	05/26/94	W.I.P.O.			
9 3 /	2 3 4 0 1	11/25/93	W.I.P.O.			
9 2 /	1 2 9 6 1	08/06/92	W.I.P.O.			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P22618	Serial No. 10/631,795
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Kouichi SEKIYA et al.	
				Filing Date August 1, 2003	Group 1624
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	1	First Page of JP 4-253945.			
	2	First Page of JP50-157360.			
	3	First Page of JP 6-504782.			
	4	First Page of JP 9-500376.			
	5	First Page of JP 7-504442.			
	6	First Page of JP 8-501318.			
	6	Angyal, A.M. et al., "Purines as Amplifiers of the Antibiotic Activity of Phleomycin Against <i>Escherichia coli</i> B," J. Gen. Microbiology, (1974), 85, 163-68.			
	8	Beavo, J.A., Multiple Isozymes of Cyclic Nucleotide Phosphodiesterase, Adv. Second Messenger Phosphoprotein Res., 22, 1-38 (1988).			
	9	Beavo, J.A. and Reifsnnyder, D.H., Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the design of Selective Inhibitors, Trends Pharm. Sci., 11, 150-155 (1990).			
1	0	Hidaka, H. and Shibuya, M., A New Assay of Cyclic Nucleotide Phosphodiesterase; its Application to Human Serum, Biochem. Med. 10, 301-311 (1974).			
1	1	C.D. Nicholson, S.A. Jackman & R. Wilke, The ability of denbufylline cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site, Br. J. Pharmacol, (1989), 97, 889-897.			
1	2	Torphy, T.J. and Undem, B.J., Phosphodiesterase Inhibitors: New Opportunities for the Treatment of Asthma, Thorax, 46, 512-523 (1991).			
1	3	Global Initiative for Chronic Obstructive Lung Disease (NIH, National Heart, Lung and Blood Institute) page 6.			
1	4	Makino et al., International Archives of Allergy and Immunology, 121(Suppliment 1) pages 4, 5, 54, 33, 36-39(2000).			
1	5	Giembycz, Drugs 59(2), 193 (2000).			
1	6	Benjamin K. Gill, "Diagram Representing the Roles of Cytokines in Inflammatory Responses" http://attila.stevens-tech.edu/chembio/bgill/IL_10K.html .			
EXAMINER			DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					